Philips and Anumana Partner to Launch ECG AI Marketplace for Enhanced Cardiac Diagnostics

Philips has unveiled its ECG AI Marketplace, a centralized platform designed to transform how cardiac care teams access and implement AI-powered diagnostic tools across U.S. healthcare systems. The marketplace addresses a growing challenge in healthcare technology adoption by consolidating multiple vendor offerings into a single, manageable interface that integrates seamlessly with existing Philips infrastructure.

Anumana, an AI-driven health technology company specializing in cardiac care transformation, serves as the marketplace's inaugural partner. The company's FDA-cleared ECG-AI™ LEF (Low Ejection Fraction) algorithm represents the platform's flagship offering, now available across Philips' comprehensive ECG portfolio, including IntelliSpace ECG and Philips cardiographs.

The marketplace directly tackles operational inefficiencies that have plagued healthcare organizations managing disparate AI platforms. By centralizing vendor connections and eliminating the need for dedicated IT resources to oversee multiple interfaces, hospitals can significantly reduce operational costs while improving workflow efficiency. This streamlined approach enables clinicians to access a broad portfolio of validated AI tools at the point of care, substantially reducing time spent reviewing ECG results and expediting patient diagnoses.

Anumana's LEF algorithm, which carries FDA breakthrough designation, analyzes standard 12-lead resting ECGs to identify reduced ejection fraction—a critical early indicator of heart failure. This integration allows healthcare providers to access AI-powered cardiac insights during routine ECG ordering and interpretation, supporting more timely and informed clinical decision-making.

"We're proud to be the flagship offering on the Philips ECG AI Marketplace," said Simos Kedikoglou, MD, President and Chief Operating Officer at Anumana. "Working with Philips expands access to our ECG-AI technology through a trusted platform, starting with our cleared LEF algorithm and extending to our full suite of point-of-care algorithms as they receive FDA regulatory clearance. Anumana's AI algorithms, including for LEF detection, have been extensively evaluated in studies involving more than 150,000 patients and are supported by nearly 100 peer-reviewed publications. By making early detection tools available across multiple platforms, this collaboration helps clinicians intervene sooner, reflecting a shared commitment to improving outcomes for patients at risk of heart failure."

The partnership represents a strategic advancement in cardiac care delivery, positioning both companies at the forefront of AI-enabled healthcare transformation while establishing a scalable model for future algorithmic innovations in cardiovascular diagnostics.

Click here for the original news story.